18:28 , Dec 22, 2017 |  BioCentury  |  Finance

Modulating mechanism

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials...
23:35 , Aug 8, 2017 |  BC Extra  |  Company News

Depomed plummets on reduced sales guidance

Four weeks after reiterating its 2017 revenue guidance, Depomed Inc. (NASDAQ:DEPO) disappointed investors by lowering its top-line outlook when it reported 2Q17 earnings on Monday after market close. The company lost a third of its...
23:41 , Jun 15, 2017 |  BC Innovations  |  Translation in Brief

MicroRNA's big role in pain

In Science this month, Karolinska Institute researchers uncovered the mechanism of a microRNA complex in pain and showed it functions in a neuronal population not currently targeted by any therapeutics. The authors believe the neurons...
01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

XenoPort, Arbor Pharmaceuticals deal

Specialty pharma Arbor will acquire XenoPort for $7.03 per share in a cash deal the companies say values XenoPort at $467 million. The price is a 60% premium to XenoPort’s close of $4.40 on May...
00:21 , May 24, 2016 |  BC Extra  |  Company News

Arbor acquiring XenoPort

Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or about $467 million. The deal will give Arbor rights to Horizant gabapentin enacarbil , which is approved in...
01:21 , Mar 29, 2016 |  BC Extra  |  Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

XenoPort Inc. (NASDAQ:XNPT) granted Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) exclusive, U.S. rights to develop and commercialize XP23829 , which has completed a Phase II trial to treat moderate to severe chronic plaque-type psoriasis. The compound...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

XP23829: Development discontinued

XenoPort discontinued development of XP23829 and plans to partner the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort reported data from a Phase II trial of XP23829 to...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

XenoPort neurology, autoimmune news

XenoPort will reduce headcount by 25 (14%) to about 155 and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. Cuts include positions related to the XP23829 program. Additionally,...